NICE approves use of Zytiga prior to chemotherapy

New guidance in England has expanded coverage of treatment with abiraterone acetate (Zytiga) + prednisone for men with metastatic castration-resistant prostate cancer (mCRPC).

According to a media release from the National Institute for Health Care and Clinical Excellence (NICE), abiraterone + prednisone (or prednisolone) can now be used under the National Health Service to treat men with mCRPC who have no symptoms or only mild symptoms of their disease after androgen deprivation therapy (ADT) has failed, and before chemotherapy is indicated. This form of treatment had previously been approved for use only in men who had progressed on ADT and also progressed again after docetaxel-based chemotherapy.

Apparently NICE and the manufacturer of Zytiga (Janssen) came to a pricing agreement under which the company will rebate the drug cost of Zytiga from the 11th month until the end of treatment for men who are able to remain on treatment for more than 10 months.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: